RIGHT. ON TIME. — India's Trusted Nuclear Medicine, Radiotherapy & Oncology Partner for the last 40 years

+91 11 4077 6666 saxsons@saxsons.com

7 Sept 2026📖 Free full textPeer-ReviewedPubMedResearch ArticleTherapeuticEndokrynologia Polska · 2026

Effective treatment of carcinoid syndrome with peptide receptor radionuclide therapy.

Musiałkiewicz J, Komarnicki P, Maciejewski A, Ziółkowska P, Czepczyński R, Gut P (+1 more)

📖 Read the full paper (free)doi:10.5603/ep.113173 →

Identifiers

PubMed ID: 42703790

DOI: 10.5603/ep.113173

Radar topics

Lu-177 DOTATATE

Relevant Saxsons product

Product details →Knowledge Hub →

Related in the same topic

EJNMMI reports · 2026

Future scenarios of radioligand therapy in pheochromocytomas and paragangliomas.

Cell death discovery · 2026📖 Free

Immunogenic cell death as a mechanism of synergy between sunitinib and ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors.

Frontiers in medicine📖 Free

Editorial: Recent advances in theranostics: endocrine tumours and beyond

Expert opinion on pharmacotherapy · 2026

New and emerging somatostatin therapies for neuroendocrine tumors: "what is in the pipeline".

BMC cancer · 2026📖 Free

Profiling proteomic responses in small intestinal neuroendocrine tumor GOT1 after [¹⁷⁷Lu]Lu-DOTATATE therapy.

Frontiers in Pharmacology · 2026📖 Free

Combined radioligand therapy and immunotherapy for cancer: research advances and translational challenges

Search all papers →Browse every paper →More Lu-177 DOTATATE research →